HER2-positive breast cancer: incidence, prognosis, and treatment options. Am J Cancer. 2003; 2 :169–179.Estevez LG, Seidman AD. HER2-positive breast cancer: incidence, prognosis, and treatment options. Am J Cancer. 2003;2:169-179.
We also revealed that CD44+/CD24− phenotype is an independent factor for poor prognosis in patients with HER2-positive primary breast cancer not treated with adjuvant trastuzumab, indicating that the BCSC phenotype is associated with poor clinical outcome in HER2-positive breast cancer. To the ...
Although this study suggests important findings with respect to HER2 status in good prognosis tumours, we accept the study's limitations with respect to the small number of HER2-positive patients in the cohort. Even within this restricted cohort, HER2-positive patients were less likely to be grade...
[8] Maurer C, Tulpin L, Moreau M, et al. Risk factors for the development of brain metastases in patients with HER2-positive breast cancer. ESMO Open. 2018 Oct 24;3(6):e000440. [9] Darlix A, Louvel G, Fraisse J, et al. Impact of breast cancer molecular subtypes on the inciden...
[7]Identification of biologically-driven HER2-positive breast cancer subgroups associated with prognosis after adjuvant trastuzumab in the ALTTO trial.ESMO 2022.139MO [8]HER2DX genomic test in HER2-positive/hormone receptor-positive(HER2+/HR+)brea...
[9] van Mackelenbergh MT, Loibl S, Untch M, et al. Pathologic Complete Response and Individual Patient Prognosis After Neoadjuvant Chemotherapy Plus Anti-Human Epidermal Growth Factor Receptor 2 Therapy of Human Epidermal...
[22]Browne IM, André F, Chandarlapaty S, et al. Optimal targeting of PI3K-AKT and mTOR in advanced oestrogen receptor-positive breast cancer. Lancet Oncol 2024;25(4):e139-e151. [23]Zhu K, Wu Y, He P, et al. PI3K/AKT/mTOR-Targeted Therapy for Breast Cancer. Cells 2022;11(16)...
breast cancer DFS: disease-free survival ER+: estrogen receptor positive ER-: estrogen receptor negative HER2+: human epidermal growth factor receptor 2 positive HR+: hormone receptor positive HR-: hormone receptor negative PR+: progesterone receptor positive PR-: progesterone receptor neg...
This study evaluated by immunohistochemistry (IHC) immune cell response during neoadjuvant primary systemic therapy (PST) with trastuzumab in patients with HER2-positive primary breast cancer. In all, 23 patients with IHC 3+ primary breast cancer were tr
The development of several HER2-targeted agents, including monoclonal antibodies, tyrosine-kinase inhibitors and antibody–drug conjugates, has increased cure rates in patients with early stage HER2-positive (HER2+) breast cancer and substantially improved survival for patients with advanced-stage HER2+ ...